

## APPENDICES

Cumulative indices for 2006

### Author Index

- Abdollahi M  
3(1), 113–117  
3(1), 119–123  
3(3), 413–419
- Abruzzo GK  
3(4), 521–526
- Afshari M  
3(1), 119–123
- Agnese V  
3(3), 401–407
- Agrawal A  
3(4), 475–484
- Ahmed M  
3(1), 1–3
- Aidietis A  
3(1), 125–138
- Akman A  
3(1), 139–151
- Al-Mosawi AJ  
3(5), 605–607
- Alpsoy E  
3(1), 139–151
- Amsden GW  
3(3), 359–365
- Antoniou KM  
3(1), 163–174
- Arora S  
3(3), 409–412
- Astanehi-Asghari F  
3(1), 119–123
- Athwal D  
3(4), 535–545
- Augello C  
3(3), 401–407
- Badalamenti GE  
3(3), 401–407
- Baiaty A  
3(1), 113–117
- Barnett AH  
3(3), 339–348
- Barua JM  
3(3), 397–400
- Bazan V  
3(3), 401–407
- Beaulieu J  
3(1), 69–78
- Beck M  
3(1), 9–17
- Bellary S  
3(3), 339–348
- Benohanian A  
3(5), 591–596
- Blondeau JM  
3(5), 619–650
- Bonicalzi V  
3(5), 651–677
- Born L  
3(1), 153–162
- Bouros D  
3(1), 163–174
- Braverman AS  
3(5), 609–612
- Brook NR  
3(3), 421–430
- Brown D  
3(4), 535–545
- Brunton S  
3(4), 527–534
- Bubb C  
3(3), 409–412
- Cackett P  
3(3), 401–402
- Calò V  
3(3), 401–407
- Cameron JR  
3(3), 401–402
- Canavero S  
3(5), 651–677
- Cappellini MD  
3(4), 453–460
- Cascio S  
3(3), 401–407
- Chalmers LM  
3(4), 495–498
- Chamberlain MC  
3(4), 495–498
- Chowdhary SA  
3(4), 495–498
- Cicero AFG  
3(5), 559–569
- Clarke A  
3(3), 349–357
- Cohen IT  
3(5), 571–578
- Colquhoun AJ  
3(3), 421–430
- Derosa G  
3(5), 559–569
- Deshmogh M  
3(3), 409–412
- DiBaise JK  
3(1), 55–67
- Dieter RS  
3(1), 1–3  
3(4), 517–520
- Dupont C  
3(1), 69–78
- Eftekhar B  
3(3), 413–419
- Eftekhari R  
3(3), 413–419
- El-Atat F  
3(3), 409–412
- Ellegard EK  
3(1), 89–92
- Ellegard LH  
3(1), 89–92
- El-Tamer M  
3(5), 609–612
- Esmaily H  
3(3), 413–419
- Flattery AF  
3(4), 521–526
- Foulkes R  
3(4), 535–545
- Fricano S  
3(3), 401–407
- Gauthier GM  
3(4), 517–520
- Gebbi N  
3(3), 401–407
- Gebhardt MC  
3(4), 499–508
- Gebreegziabher Y  
3(3), 409–412
- Geriniere L  
3(3), 367–378  
3(5), 579–590
- Ghaffarzadeh M  
3(3), 413–419
- Ghameinezhad S  
3(1), 113–117
- Gill CJ  
3(4), 521–526
- Giordano A  
3(3), 401–407
- Gliwa A  
3(3), 409–412
- Green MR  
3(4), 495–498
- Gregorio V  
3(3), 401–407
- Hadidi E  
3(3), 413–419
- Halmesmäki KH  
3(4), 509–516
- Harmon DC  
3(4), 499–508
- Hehmat R  
3(1), 119–123
- Hickey EJ  
3(4), 521–526
- Hornicek FJ  
3(4), 499–508
- Hosseinnezhad A  
3(1), 119–123
- Hunt MA  
3(1), 97–112
- Hurskainen RA  
3(4), 509–516
- Ikram S  
3(1), 1–3
- Jahke K  
3(1), 97–112
- Jankovic J  
3(3), 349–357
- Joseph L  
3(3), 409–412
- Kamenova B  
3(5), 609–612
- Khajavi MR  
3(3), 413–419
- Kiralp MZ  
3(5), 597–603
- Kollias G  
3(4), 535–545
- Kraemer DF  
3(1), 97–112
- Kumar KE  
3(5), 613–617
- Larijani B  
3(1), 119–123
- Lebert F  
3(1), 93–96
- Lee AYY  
3(4), 461–474
- Lemieux P  
3(1), 69–78
- Lip GYH  
3(4), 445–448
- Lip PL  
3(3), 431–438
- Lombardi KM  
3(4), 495–498
- Malekirad AA  
3(1), 113–117
- Mankin HJ  
3(4), 499–508
- Marinskis G  
3(1), 125–138
- Maron L  
3(1), 97–112
- McFarlane SI  
3(3), 329–333  
3(3), 409–412
- Mellish D  
3(3), 409–412
- Mellon J  
3(3), 421–430
- Menon VJK  
3(3), 431–438
- Misura AS  
3(4), 521–526
- Miyasaka N  
3(3), 379–378
- Mohammadirad A  
3(1), 113–117  
3(1), 119–123
- Mojtahedzadeh M  
3(3), 413–419
- Mojtahedi A  
3(1), 119–123
- Morris B  
3(3), 401–402
- Muldoon LL  
3(1), 97–112

- Najafi A  
3(3), 413–419
- Nanjundappa A  
3(1), 1–3  
3(4), 517–520
- Napoli L  
3(3), 401–407
- Nesbitt A  
3(4), 535–545
- Neuwelt EA  
3(1), 97–112
- Nicasio J  
3(3), 409–412
- Nikfar S  
3(3), 413–419
- Orbay P  
3(1), 97–112
- Ormerod AD  
3(3), 439–450
- Paavonen JA  
3(4), 509–516
- Pacanowski J Jr  
3(1), 1–3
- Paknejad MH  
3(3), 413–419
- Patel N  
3(5), 609–612
- Phillips SD  
3(1), 153–162
- Popplewell A  
3(4), 535–545
- Rajpara SM  
3(3), 439–450
- Ranjbar A  
3(1), 113–117
- Rao S  
3(5), 609–612
- Rezaie A  
3(1), 119–123
- Rouini MR  
3(3), 413–419
- Rundek T  
3(3), 329–333
- Rusconi S  
3(1), 79–88
- Russo A  
3(3), 401–407
- Sahraian MA  
3(3), 413–419
- Salvadeo SAT  
3(5), 559–569
- Santini D  
3(3), 401–407
- Satyanarayana S  
3(5), 613–617
- Sawhney H  
3(5), 609–612
- Schwartz J RL  
3(3), 379–396
- Scoppettuolo E  
3(3), 401–402
- Sekhar JR  
3(5), 613–617
- Shantsila E  
3(4), 445–448
- Shatzkes J  
3(3), 409–412
- Shergill IS  
3(3), 397–400
- Singh J  
3(3), 401–402
- Sisto PS  
3(3), 401–407
- Soleimani V  
3(3), 413–419
- Souquet PJ  
3(3), 367–378  
3(5), 579–590
- Spitali M  
3(4), 535–545
- Stephens S  
3(4), 535–545
- Tatum M  
3(3), 359–365
- Tendler A  
3(5), 609–612
- Tuppurainen MT  
3(4), 509–516
- Turgay A  
3(1), 19–38
- Tyson RM  
3(1), 97–112
- Tzouvelekis A  
3(1), 163–174
- Uzun G  
3(5), 597–603
- Vazquez JA  
3(1), 39–54
- Vigano O  
3(1), 79–88
- Watson T  
3(4), 445–448
- Weedon J  
3(5), 609–612
- Weir N  
3(4), 535–545
- Whorwell P  
3(4), 475–484
- Wolff MR  
3(4), 517–520
- Woo PN  
3(3), 439–450
- Wyndaele JJ  
3(4), 485–494
- Yildiz S  
3(5), 597–603
- Young K  
3(5), 553
- Zamani MJ  
3(3), 413–419
- Zamani H  
3(1), 113–117
- Zinga D  
3(1), 153–162
- Alefaccept3(3), 439–450
- Alfentanil  
3(5), 651–677
- Alteplase  
3(1), 163–174
- Alemtuzumeb  
3(4), 535–545
- Aluminium acetate  
3(1), 139–151
- Amantadine  
3(5), 651–677
- Amiodarone  
3(1), 125–138  
3(5), 571–578
- Amitriptyline  
3(5), 651–677
- Amlexanox  
3(1), 139–151
- Amoxicillin  
3(4), 527–534  
3(5), 619–650
- Amphetamine  
3(1), 19–38
- Amphotericin B  
3(1), 39–54
- Amprenavir (APV)  
3(1), 79–88
- Angiotensin-converting enzyme inhibitors  
3(1), 125–138
- Anidulafungin  
3(1), 39–54
- Anthracycline  
3(1), 97–112
- Antidepressants  
3(1), 19–38
- Anti-HIV-1  
3(1), 79–88
- Antiangiogenic agents  
3(3), 431–438
- Antihyperglycemic therapy  
3(3), 339–348
- Antihypertensives  
3(1), 19–38
- Antipseudomonal penicillins  
3(1), 163–174
- Antipseudomonal quinolones  
3(1), 163–174
- Antitumor necrosis factor- $\alpha$   
3(1), 139–151
- Arixtra®  
3(4), 461–474
- Armodafinil  
3(3), 389–396
- Aspirin  
3(5), 651–677
- Compound Index**
- 2,4,6-tripyriddy-5-triazine  
3(1), 113–117
- 2-thiobarbituric acid  
3(1), 113–117
- 5-fluorouracil  
3(1), 97–112  
3(5), 609–612
- <sup>99m</sup>Tc-glucuheptonate  
3(1), 97–112
- <sup>99m</sup>Tc-albumin  
3(1), 97–112
- $\alpha$ -lipoic acid  
3(5), 613–617
- Acarbose  
3(5), 559–569
- Acetylcholinesterase  
3(1), 93–96
- Acute brain injury  
3(3), 413–419
- Acute urinary retention  
3(3), 421–430
- Acyclovir  
3(5), 651–677
- Adalimumab  
3(3), 379–387  
3(3), 439–450  
3(4), 535–545
- Adderal XR® (see psychostimulants)
- Adriamycin  
3(1), 97–112
- Aerodose®  
(see inhaled human insulin)
- AERx® (see inhaled human insulin)
- AG-001859  
3(1), 79–88
- AG1478  
3(3), 421–430
- Age-related macular degeneration  
3(3), 431–438
- AIR system  
(see inhaled human insulin)
- AIR® (see inhaled human insulin)
- Aldosterone receptor blockers  
3(1), 125–138

## APPENDICES

Cumulative indices for 2006

Astemizole 3(5), 619–650	Capecitabine 3(1), 97–112	Cholinesterase inhibitors 3(1), 93–96	3(4), 450 3(5), 619–650
Atazanavir 3(1), 79–88	Capsaicin 3(5), 651–677	Choroidal neovascularization 3(3), 431–438	Cylcosporin A 3(1), 139–151
Atomoxetine hydrochloride 3(1), 19–38	Carbamazepine 3(1), 39–54	Cimetidine 3(5), 571–578	3(3), 367–378
Azalide 3(5), 619–650	3(5), 619–650	<i>Cinnamomum zeylanicum</i> 3(1), 113–117	Dalteparin 3(4), 461–474
Azathioprine 3(1), 139–151	Carbapenems 3(1), 163–174	Ciprofloxacin 3(1), 163–174	Darifenacin 3(4), 485–494
Azimilide 3(4), 445–448	Carboplatin 3(1), 97–112	Cisapride 3(4), 475–484	Deferasirox 3(4), 453–460
Azithromycin 3(3), 359–365 3(4), 527–534 3(5), 619–650	3(5), 579–590	Cisplatin 3(1), 97–112 3(3), 367–378 3(5), 579–590	Deferiprone 3(4), 453–460
Azoles 3(1), 39–54	Carvedilol 3(1), 119–123	Citalopram 3(1), 153–162 3(5), 651–677	Dapsone 3(1), 139–151
Aztreonam 3(1), 163–174 3(5), 619–650	Caspofungin 3(1), 39–54	Cataplexy 3(3), 389–396	Desferal® 3(4), 453–460
β-blocker 3(1), 125–138 3(1), 119–123 3(4), 445–448	Catapres® (see clonidine)	Cefepime 3(5), 619–650	Desipramine 3(1), 19–38 3(5), 651–677
β-lactoglobulin 3(1), 69–78	Cefepime 3(5), 619–650	Cefotaxime 3(5), 619–650	Dexamethasone 3(1), 39–54 3(1), 69–78 3(5), 571–578
β-lactotensin 3(1), 69–78	Cefpodoxime 3(5), 619–650	Cefpodoxime 3(5), 619–650	Dexedrine® (see dextroamphermine)
Baclofen 3(5), 651–677	Cefprozil 3(5), 619–650	Clindamycin 3(1), 163–174 3(5), 619–650	Dextroamphermine 3(1), 19–38
Benzatin penicillin 3(1), 139–151	Ceftriaxone 3(5), 619–650	Clomipramine 3(5), 651–677	Dextromethorphan 3(5), 651–677
Benzylamine 3(1), 139–151 3(5), 651–677	Cefuroxime 3(4), 527–534	Clonazepam 3(1), 153–162 3(5), 651–677	Dextropropoxyphene 3(5), 651–677
Bilateral angle-closure glaucoma 3(3), 421–430	Cefuroxime axetil 3(5), 619–650	Clonidine 3(1), 19–38 3(5), 651–677	Diabetes mellitus 3(3), 329–333 3(3), 339–348
BILA-2185 BS 3(1), 79–88	Cephalosporins 3(1), 163–174	CNS stimulants 3(3), 389–396	Diamorphine 3(5), 651–677
Bovine serum albumin 3(1), 69–78	Certolizumab pegol 3(4), 535–545	Codeine 3(5), 651–677	Diclofenac 3(1), 139–151
BR96-DOX 3(1), 97–112	Cetuximab 3(3), 421–430	Colchicine 3(1), 139–151	Digoxin 3(4), 445–448 3(5), 619–650
Buprenorphine 3(5), 651–677	Chemotherapy 3(3), 421–430	Concerta® (see psychostimulants)	Dihydrotestosterone 3(3), 397–400
Bupropion 3(1), 19–38 3(1), 153–162 3(5), 571–578 3(5), 651–677	Chlorambucil 3(1), 139–151	Coronary artery disease 3(3), 329–333	Dimenhydrinate 3(5), 571–578
Burow's solution 3(1), 139–151	Chloramphenicol 3(4), 521–526	Corticosteroids 3(1), 139–151	Disopyramide 3(5), 619–650
Buspiron 3(5), 651–677	Chlordiazepoxide 3(5), 651–677	CP-358-774 3(3), 421–430	Dithiobis-2-nitrobenzoic acid 3(1), 113–117
Caffeine 3(5), 619–650	Chlorhexidine 3(1), 139–151	Cremophor EL 3(3), 367–378	DMP 450® (see mozenavir)
Calcitonin 3(5), 651–677	Chlorimipramine 3(5), 651–677	Cyclophosphamide 3(1), 97–112 3(3), 367–378 3(5), 579–590	Docetaxel 3(1), 97–112 3(3), 367–378 3(5), 579–590
	Chlorpheniramine 3(5), 571–578	Cyclosporine 3(1), 39–54 3(1), 139–151 3(3), 439–450	Dolasetron 3(5), 571–578
	Chlorpromazine 3(5), 651–677		Doxepin 3(5), 651–677
	Chlorprothixene 3(5), 651–677		Doxorubicin 3(1), 97–112
	Cholinergic acetyltransferase 3(1), 93–96		

3(5), 571–578	Fluphenazine	IFN- $\alpha$ ?	Levodopa
3(5), 609–612	3(5), 651–677	3(1), 139–151	3(3), 349–357
Doxycycline	Fluvoxamine	Ifosamide	3(5), 651–677
3(3), 359–365	3(1), 93–96	3(5), 579–590	Levofloxacin
3(5), 619–650	3(1), 153–162	Imipenem	3(5), 619–650
Dronedaron	3(5), 651–677	3(5), 619–650	Lidocaine
3(4), 445–448	Focalin® (see psychostimulants)	Imipramine	3(1), 139–151
Droperidol	Fondaparinox	3(1), 19–38	3(5), 591–596
3(5), 571–578	3(4), 461–474	3(5), 651–677	3(5), 651–677
3(5), 651–677	Fragmin®	Immunoglobulin	Lincosamide
Ductal fluid	3(4), 461–474	3(1), 69–78	3(5), 619–650
3(3), 403–407	Gabapentin	Indomethacin	Linezolid
Ductal lavage	3(5), 651–677	3(5), 651–677	3(4), 521–526
3(3), 403–407	Galsulfase	Indinavir	Liposomal doxorubicin
Dutasteride	3(1), 9–17	3(1), 79–88	3(1), 97–112
3(3), 397–400	Gatifloxacin	Infliximab	Listerine
Dx Spansule® (see psychostimulants)	3(5), 553	3(1), 139–151	3(1), 139–151
Echinocardins	3(5), 619–650	3(3), 439–450	Lithium
3(1), 39–54	Gemcitabine	3(3), 379–387	3(5), 651–677
Epidermal growth factor receptor	3(1), 97–112	3(4), 535–545	Lopinavir
3(3), 421–430	3(5), 579–590	Inhaled human insulin	3(1), 79–88
Ergotamine	GI198745 (see Dutasteride)	3(3), 339–348	Lorazepam
3(5), 619–650	Glibenclamide	Insufflation	3(1), 153–162
Erlotinib	3(3), 339–348	3(3), 403–407	3(5), 651–677
3(3), 421–430	3(5), 559–569	Interferon	Low-density lipoprotein
Erythromycin	Gliclazide	3(1), 139–151	3(3), 329–333
3(4), 527–534	3(5), 559–569	Intracerebral hemorrhage	Luciferase
3(5), 619–650	3(5), 613–617	3(3), 413–419	3(1), 97–112
Estrogen	Glimepride	Intravenous aminopenicillin	Macrolides
3(5), 609–612	3(5), 559–569	3(1), 163–174	3(3), 359–365
Etanercept	Glipizide	Iressa® (see Gefitinib)	3(5), 619–650
3(1), 139–151	3(5), 559–569	Itraconazole	Macula
3(3), 379–387	Glutamine	3(1), 39–54	3(3), 431–438
3(3), 439–450	3(1), 55–67	Josamycin	Malonedialdehyde
Etoposide	Glutathione	3(5), 619–650	3(1), 113–117
3(1), 97–112	3(1), 113–117	Kelolides	Mannitol
Etoposide phosphate	Glycopyrrolate	3(4), 527–534	3(1), 97–112
3(1), 97–112	3(5), 591–596	Ketamine	Maprotiline
Excessive sleepiness	Glycyl-leucyl-phenylalanine	3(5), 651–677	3(5), 651–677
3(3), 389–396	3(1), 69–78	Ketanserin	Memantine
Exjade®	Granisetron	3(5), 651–677	3(5), 651–677
3(4), 453–460	3(5), 571–578	Ketobemidone	Mepivacaine
Exubera® (see inhaled human insulin)	Guanfacine	3(5), 651–677	3(1), 139–151
Fentanyl	3(1), 19–38	Lactoferrin	Meropenem
3(5), 651–677	GW640385	3(1), 69–78	3(5), 619–650
First-generation HIV-1 protease	3(1), 79–88	Lamotrigine	Metadate CD® (see psychostimulants)
inhibitors	Haloperidol	3(5), 651–677	Metadone
3(1), 79–88	3(5), 651–677	Lapatinib	3(5), 651–677
Flecainide	Herstatin	3(1), 97–112	Metformin
3(4), 445–448	3(1), 97–112	3(3), 421–430	3(3), 339–348
3(5), 651–677	Hexetidinie	Laronidase	3(5), 559–569
Fluoroquinolone	3(1), 139–151	3(1), 9–17	Methadone
3(5), 619–650	Hydrocodone	Levomepromazine	3(5), 571–578
Fluoxetine	3(5), 651–677	3(5), 651–677	3(5), 651–677
3(1), 19–38	IFN-2 $\alpha$	Levamisole	Methandienon
3(1), 153–162	3(1), 139–151	3(1), 139–151	3(5), 605–607
3(5), 651–677			

## APPENDICES

Cumulative indices for 2006

Methicillin 3(5), 619–650	Nateglinide 3(3), 329–333	Penicillin 3(1), 163–174 3(5), 619–650	Repaglinide 3(5), 559–569
Methotrexate 3(1), 97–112 3(1), 139–151 3(3), 379–387 3(3), 439–450 3(4), 450 3(4), 495–498 3(4), 535–545 3(5), 609–612	Nefazodone 3(1), 153–162	Pentobarbital 3(5), 651–677	Resistant–Repellent™ (see SPI-70095)
Methylin ER® (see psychostimulants)	Nelfinavir 3(1), 79–88	Perphenazine 3(5), 651–677	Rifampin 3(1), 39–54 3(5), 571–578
Methylphenidate 3(1), 19–38	Naloxone 3(5), 651–677	Phenitoyn 3(5), 651–677	Riluzole 3(5), 651–677
Methylphenidate SR® (see psychostimulants)	Nicardipine 3(5), 651–677	Phenobarbital 3(1), 153–162	Ritalin LA® (see psychostimulants)
Methylprednisolone 3(1), 139–151 3(5), 619–650	Nucleoside 3(1), 79–88	Phenoxyethylpenicillin 3(5), 619–650	Ritalin SR® (see psychostimulants)
Methypatch® (see psychostimulants)	Non-nucleoside inhibitors of reverse transcriptase 3(1), 79–88	Pimozide 3(5), 651–677	Ritalin® (see methylphenidate)
Metoclopramide 3(5), 571–578	Nortriptyline 3(5), 651–677	Pioglitazone 3(5), 559–569	Ritonavir 3(1), 79–88 3(5), 571–578
Metronidazole 3(5), 619–650	Octreotide 3(5), 651–677	Piperacillin 3(5), 619–650	Rituximab 3(4), 535–545
Mexiletine 3(5), 651–677	Ondansetron 3(1), 97–112 3(5), 571–578	Piracetam 3(1), 93–96	Rosiglitazone 3(3), 339–348 3(5), 559–569
Mianserin 3(5), 651–677	Orabase 3(1), 139–151	Pioglitazone 3(3), 329–333	Rosuvastatin 3(3), 329–333
Micafungin 3(1), 39–54	Oral retinoids 3(3), 439–450	PL100 3(1), 79–88	Roxithromycin 3(5), 619–650
MicroDose (see inhaled human insulin)	Orally disintegrating tablet 3(3), 349–357	Posaconazole 3(1), 39–54	Saquinavir 3(1), 79–88
Microsphere formulation 3(3), 359–365	Ovalbumin 3(1), 69–78	Pregabalin 3(5), 651–677	Scopolamine 3(4), 495–498 3(5), 571–578
Midazolam 3(5), 619–650 3(5), 651–677	Oxalbumin 3(1), 69–78	Prednisolone 3(1), 139–151	Second-generation cephalosporin 3(1), 163–174
Miglitol 3(5), 559–569	Oxaliplatin 3(1), 97–112	Prednisone 3(1), 97–112	Selective estrogen–receptor modulator 3(3), 403–407
Mitomycin 3(5), 579–590	Oxandrolone 3(5), 605–607	Prilocaine 3(5), 591–596	Selective serotonin reuptake inhibitor 3(3), 421–430
Moclobemide 3(5), 651–677	Oxazolone 3(1), 69–78	Promethazine 3(5), 571–578	Selective norepinephrine reuptake inhibitor 3(1), 19–38 3(1), 153–162
Modafinil 3(3), 389–396	Oxybutynin 3(4), 485–494	Provigil® (see modafinil)	Selegiline 3(3), 349–357
Morphine 3(5), 571–578 3(5), 651–677	Oxycodone 3(5), 651–677	Propanteline 3(4), 485–494	Serotonin selective re–uptake inhibitors 3(1), 93–96 3(3), 421–430
Moxifloxacin 3(5), 619–650	Paclitaxel 3(1), 1–3 3(1), 97–112 3(3), 367–378 3(5), 579–590	Propafenone 3(4), 445–448	Sertraline 3(1), 153–162
Mozenavir 3(1), 79–88	Pandropazole 3(4), 495–498	Propofol 3(5), 571–578 3(5), 651–677	Several second-generation protease inhibitors 3(1), 79–88
Myocardial infarction 3(3), 329–333	Paracetamol 3(5), 597–603	Prostaglandin E1 3(5), 651–677	SGN-15 3(1), 97–112
Myoscint® 3(4), 535–545	Paroxetine 3(1), 19–38 3(1), 93–96 3(1), 153–162 3(5), 651–677	Psoralen 3(3), 439–450	Silver nitrate 3(1), 139–151
Nandrolone decanoate 3(5), 605–607	Paxil® (see paroxetine)	Psychostimulants 3(1), 19–38	Sirolimus 3(1), 1–3
Narcolepsy 3(3), 389–396	PD153035 3(3), 421–430	Quinazoline 3(3), 421–430	Sodium amyltal 3(5), 651–677
		Quinidine 3(5), 571–578	Sodium oxybate 3(3), 389–396
		Ranitidine 3(5), 571–578	
		Recombinant human growth hormone 3(1), 55–67	

Sodium thiosulfate 3(1), 97–112	Tedisimile 3(4), 445–448	Topoisomerase I agents 3(1), 97–112	Valproate 3(5), 619–650
Solifenacin 3(4), 485–494	Tegaserod 3(4), 475–484	Topoisomerase II agents 3(1), 97–112	Valsartan 3(3), 329–333
Somatropin 3(1), 55–67	Tenex® (see guanfacine)	Tolterodine 3(4), 485–494	Vancomycin 3(1), 163–174
Sotalol 3(1), 125–138	Terfenadine 3(5), 619–650	Transient ischemic attack 3(3), 329–333	Venlafaxine 3(1), 153–162
SPI-70095 3(1), 79–88	Testosterone 3(3), 397–400	Transitional cell carcinoma 3(3), 421–430	Venlafaxine 3(5), 651–677
Spiros® (see inhaled human insulin)	Tetracaine 3(1), 139–151	Trastuzumab 3(1), 97–112	Venlafaxine 3(1), 19–38
SPSS® 3(3), 409–412	Tetracycline 3(1), 139–151	3(3), 421–430	Verapamil 3(1), 125–138
Statins 3(1), 125–138 3(4), 445–448	Tetraethoxypropane 3(1), 113–117	3(4), 449	Verteporfin 3(3), 431–438
Strattera® (see atomoxetine hydrochloride)	Tetrahydrofuran 3(1), 79–88	Traumatic brain injury 3(3), 413–419	Vigabatrin 3(5), 651–677
Streptodornase 3(1), 163–174	Thalidomide 3(1), 139–151	Trazodone 3(1), 93–96 3(1), 153–162	Vincristine 3(1), 97–112
Streptodornase-a 3(1), 163–174	Theophylline 3(5), 619–650	3(5), 651–677	Vindesine 3(5), 579–590
Streptokinase 3(1), 163–174	Thiamylal 3(5), 651–677	Triamcinolone acetonide 3(1), 139–151	Vinorelbine 3(1), 97–112
Sucralfate 3(1), 139–151	Thiopental 3(5), 651–677	Triazolam 3(5), 619–650	3(5), 579–590
Sulfamethoxazole 3(5), 619–650	Thiopentone 3(5), 651–677	Trichloroacetic acid 3(1), 113–117	Voriconazole 3(1), 39–54
Superparamagnetic iron oxide nanoparticles 3(1), 97–112	Thrombocytopenia 3(3), 367–378	Tricyclic antidepressants 3(1), 19–38	Warfarin 3(5), 619–650
Tacrolimus 3(1), 39–54	Third-generation cephalosporins 3(1), 163–174	Tricyclics 3(1), 153–162	Welbutrin® (see bupropion)
Tamoxifen 3(1), 19–38 3(3), 403–407 3(5), 609–612	Tiagabine 3(5), 651–677	Tris base 3(1), 113–117	ZD1839 3(3), 421–430
Tarceva® (see erlotinib)	Tiapride 3(5), 651–677	Tricyclic antidepressants 3(3), 401–402	Ximelagatran 3(4), 461–474
Taxane 3(3), 367–378	Tipranavir 3(1), 79–88	Trimethoprim 3(5), 619–650	Ziconotide 3(5), 651–677
Taxol® (see paclitaxel)	Tizanidine 3(5), 651–677	Trospium 3(4), 485–494	Zidovudine 3(5), 619–650
Taxotere® (see docetaxel)	TMC 114 3(1), 79–88	Trovafloxacin 3(5), 553	Zimelidine 3(5), 651–677
Tazobactam 3(5), 619–650	TMC 126 3(1), 79–88	Tween 80 3(3), 367–378	Zydis® (see selegiline)
Technosphere® (see inhaled human insulin)	Tofranil® (see imipramine)	Tygacil® 3(4), 449	Zyvox 3(4), 521–526
	Topiramate 3(5), 651–677	Tyr-gly-gly 3(1), 69–78	